Teacher Retirement System of Texas Lowers Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Teacher Retirement System of Texas lessened its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 9.3% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 12,427 shares of the company’s stock after selling 1,281 shares during the period. Teacher Retirement System of Texas’ holdings in Pacira BioSciences were worth $309,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Sterling Capital Management LLC raised its position in Pacira BioSciences by 779.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock valued at $26,000 after purchasing an additional 1,208 shares in the last quarter. Ancora Advisors LLC purchased a new stake in Pacira BioSciences during the fourth quarter valued at about $26,000. Wealthquest Corp purchased a new stake in Pacira BioSciences during the first quarter valued at about $59,000. PNC Financial Services Group Inc. raised its position in Pacira BioSciences by 16.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock valued at $68,000 after purchasing an additional 513 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in Pacira BioSciences by 112.8% during the first quarter. GAMMA Investing LLC now owns 3,694 shares of the company’s stock valued at $92,000 after purchasing an additional 1,958 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Insider Activity

In other news, SVP Lauren Riker sold 5,578 shares of Pacira BioSciences stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $26.21, for a total transaction of $146,199.38. Following the completion of the transaction, the senior vice president directly owned 59,564 shares in the company, valued at approximately $1,561,172.44. This trade represents a 8.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.40% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. HC Wainwright raised their price objective on Pacira BioSciences from $48.00 to $65.00 and gave the company a “buy” rating in a research note on Tuesday, April 8th. Needham & Company LLC reduced their price objective on Pacira BioSciences from $32.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Finally, Wall Street Zen raised Pacira BioSciences from a “hold” rating to a “buy” rating in a research note on Friday, June 6th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $26.44.

Pacira BioSciences Stock Performance

Shares of PCRX opened at $21.59 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.41 and a quick ratio of 1.99. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $27.64. The company has a 50-day simple moving average of $24.54 and a two-hundred day simple moving average of $24.36. The firm has a market capitalization of $999.40 million, a PE ratio of -9.47 and a beta of 0.48.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.